Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extension Study to Evaluate the Long-term Outcomes of Subjects Following CLS-AX Administration for Age-related Macular Degeneration in the CLS-AX CLS1002-101 Study

NCT05131646 is registered in ClinicalTrials.gov with Clearside Biomedical, Inc. as lead sponsor.

NCT NCT05131646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05131646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extension Study to Evaluate the Long-term Outcomes of Subjects Following CLS-AX Administration for Age-related Macular Degeneration in the CLS-AX CLS1002-101 Study
Lead sponsor
Clearside Biomedical, Inc.
Phase
Observational
Overall status
Completed
Start date
October 8, 2021
Completion date
January 5, 2023
Enrollment
15 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration